Last update 20 Jun 2024
Aripiprazole/Escitalopram
Last update 20 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Escitalopram/aripiprazole, OPC-14597/escitalopram |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Structure
Molecular FormulaC23H27Cl2N3O2 |
InChIKeyCEUORZQYGODEFX-UHFFFAOYSA-N |
CAS Registry129722-12-9 |
View All Structures (2)
Related
1
Clinical Trials associated with Aripiprazole/EscitalopramSequential Multiple Assignment Randomized Trial for Bipolar Depression
100 Clinical Results associated with Aripiprazole/Escitalopram
Login to view more data
100 Translational Medicine associated with Aripiprazole/Escitalopram
Login to view more data
100 Patents (Medical) associated with Aripiprazole/Escitalopram
Login to view more data
100 Deals associated with Aripiprazole/Escitalopram
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Depressive Disorder | Phase 3 | US | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | AU | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | CA | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | - | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | IN | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | MY | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | MX | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | ZA | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | KR | 30 Jul 2010 | |
| Depressive Disorder | Phase 3 | TW | 30 Jul 2010 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 1,522 | (Switching: Bupropion-SR) | rvlwlrzwyx(oafjzeyqie) = bjrdylwjkd yeiiwajuhr (tmpqbjllgn, sewjtzgimi - yvlvljaaod) View more | - | 29 May 2018 | ||
(Augmenting: Antidepressant + Bupropion-SR) | rvlwlrzwyx(oafjzeyqie) = pizfmcsdqm yeiiwajuhr (tmpqbjllgn, kizndmwrob - xutdeyfhgz) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free